Federica Scarfì, Michele Lanzetti, Serena Rosati, Franca Taviti
{"title":"人源化双特异性抗体Talquetamab的皮肤安全性:与多发性骨髓瘤新免疫疗法相关的皮肤和指甲不良事件。","authors":"Federica Scarfì, Michele Lanzetti, Serena Rosati, Franca Taviti","doi":"10.23736/S2784-8671.25.08222-2","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":"160 4","pages":"386-388"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.\",\"authors\":\"Federica Scarfì, Michele Lanzetti, Serena Rosati, Franca Taviti\",\"doi\":\"10.23736/S2784-8671.25.08222-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":14526,\"journal\":{\"name\":\"Italian Journal of Dermatology and Venereology\",\"volume\":\"160 4\",\"pages\":\"386-388\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian Journal of Dermatology and Venereology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23736/S2784-8671.25.08222-2\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian Journal of Dermatology and Venereology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2784-8671.25.08222-2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Dermatological safety of humanized bispecific antibody Talquetamab: skin and nail adverse events related to a novel immunotherapy for multiple myeloma.